Price Action To Observe: Is Selling Kadmon Holdings Inc Here a Winning Strategy?

Price Action To Observe: Is Selling Kadmon Holdings Inc Here a Winning Strategy?

The stock of Kadmon Holdings Inc (NYSE:KDMN) reached all time low today, Nov, 3 and still has $4.12 target or 10.00% below today’s $4.58 share price. This indicates more downside for the $197.26 million company. This technical setup was reported by Barchart.com. If the $4.12 PT is reached, the company will be worth $19.73M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. The stock increased 1.78% or $0.08 during the last trading session, hitting $4.58. About 47,479 shares traded hands. Kadmon Holdings Inc (NYSE:KDMN) has risen 6.00% since October 4, 2016 and is uptrending. It has outperformed by 4.79% the S&P500.

Kadmon Holdings Inc (NYSE:KDMN) Ratings Coverage

Out of 4 analysts covering Kadmon Holdings (NYSE:KDMN), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Kadmon Holdings has been the topic of 4 analyst reports since August 22, 2016 according to StockzIntelligence Inc. The firm has “Buy” rating given on Monday, August 22 by Jefferies. The stock of Kadmon Holdings Inc (NYSE:KDMN) has “Neutral” rating given on Monday, August 22 by Citigroup. As per Monday, August 22, the company rating was initiated by H.C. Wainwright. JMP Securities initiated the shares of KDMN in a report on Monday, August 22 with “Outperform” rating.

According to Zacks Investment Research, “Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York.”

More recent Kadmon Holdings Inc (NYSE:KDMN) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on June 17, 2016. Also Marketwatch.com published the news titled: “Sam Waksal’s Kadmon Holdings prices IPO” on July 26, 2016. Marketwatch.com‘s news article titled: “Kadmon Holdings trading below $12 issue price in market debut” with publication date: July 27, 2016 was also an interesting one.

KDMN Company Profile

Kadmon Holdings, Inc., formerly Kadmon Holdings, LLC, is a biopharmaceutical company, which is engaged in the discovery, development and commercialization of small molecules and biologics. The Firm is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. The Company’s product candidates include KD025, Tesevatinib in Oncology, Tesevatinib in polycystic kidney disease (PKD) and KD034. It also offers tablets and capsules, such as Ribasphere RibaPak, Ribasphere tablets, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment